TRIMTECH Therapeutics announced the appointment of Dr. Mike⁢ Hutton⁣ to⁤ its Scientific Advisory Board (SAB). dr. ⁢Hutton brings decades of experience in neurodegenerative disease research and drug growth, aiming to accelerate the company’s mission to create accessible, disease-modifying treatments.

Dr. Mike‌ Hutton’s Extensive Background

Dr.Hutton most recently served as Chief Scientific Officer (CSO) and Vice president of Neurodegeneration Research and UK Site‍ Scientific leader at Eli Lilly and‍ Company. ⁣In these roles,he spearheaded drug discovery⁢ efforts for Alzheimer’s Disease,Parkinson’s Disease,and fronto-temporal dementia. Prior to Eli Lilly, he held a Senior Director position at MSD (Merck Sharp & Dohme) and was a Consultant and Professor of Neuroscience at the Mayo⁢ Clinic.

At the Mayo Clinic,Dr. Hutton’s research team made meaningful contributions to identifying the genetic causes of fronto-temporal dementia,including pinpointing mutations in the tau and progranulin ‌genes. ⁣His work on tau protein earned him both the Potamkin Prize and the MetLife⁤ Prize – prestigious awards recognizing outstanding contributions ⁤to the understanding of neurodegenerative diseases. He holds a ⁣BSc ⁢in Biochemistry from the University of Manchester and a PhD ‍in Neuroscience from the ​University of Cambridge.

“We’re delighted to welcome Mike as the newest member of our recently formed Scientific Advisory Board. his​ extensive expertise in neurodegenerative disease therapeutics will be a great asset as we continue to advance our mission to deliver first-in-class medicines to address the critical need for cost-effective, disease-modifying treatments for neurodegeneration that can reach broad patient populations.”

Dr.⁣ nicola Thompson, CEO, TRIMTECH Therapeutics

Dr. Hutton expressed⁤ his enthusiasm for TRIMTECH’s innovative ⁢approach, stating: “TRIMTECH’s‍ novel approach is leading the way in the development of small molecule CNS penetrant ‌degraders for⁣ neurological disorders, addressing the difficult to drug targets ‍underpinning these diseases.I am ​delighted to join the ⁣SAB – the Company has assembled an excellent team, and ⁢I look forward to helping guide⁢ the development of‌ these much-needed, ⁤accessible therapeutic options.”

TRIMTECH’s Focus on CNS Penetrant Degraders

TRIMTECH⁣ Therapeutics is focused on developing small molecule ‌drugs that can cross the ⁢blood-brain barrier (CNS penetrant) and selectively degrade disease-causing proteins. This approach aims to tackle⁢ neurological disorders by targeting previously “undruggable” targets, offering potential for more effective ‍and accessible treatments. ⁤ The company’s strategy centers on creating therapies ​that modify ⁤the course of⁣ neurodegenerative diseases, rather than simply managing symptoms.